Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) expects 120 million yuan to 180 million yuan in attributable loss for 2025, swinging from a profit of 39.7 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Shares of the biomedicine firm fell over 4% in late-morning trade Monday.
The company's financial results are due in late March.